Adults 18 to 60, any sex, with Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Responders vs Non-Responders Using SALT ScorePrimary· 48 weeks
The Severity of Alopecia Tool (SALT) is a measurement procedure used by dermatologists to determine the percentage of scalp hair loss. The SALT system divides the scalp into 4 areas: Top has 4 sections of 10% total are 40%, back has 4 sections of 6% total are 24% and the 2 sides, left and right, each has 2 sections of 4% and 2 sections of 5% total of 18% and 36% combined. In the beginning, the area of hair loss would be measured by checking each area for hair loss and determining the bald spots combined per SALT scale then keeping the record as SALT baseline (SALT). The total SALT score is mea
Group
Value
95% CI
Tofacitinib
9
Tofacitinib
10
Side Effects From TofacitinibSecondary· 48 weeks
Patients came back for follow-up every month during a total of 24 weeks of treatments and at weeks 28,36 and 48.
Dyslipidemia
Group
Value
95% CI
Tofacitinib
9
Upper respiratory tract infection
Group
Value
95% CI
Tofacitinib
6
Tuberculosis
Group
Value
95% CI
Tofacitinib
1
Myalgia
Group
Value
95% CI
Tofacitinib
1
Acne
Group
Value
95% CI
Tofacitinib
2
Weight gain
Group
Value
95% CI
Tofacitinib
1
Constipation
Group
Value
95% CI
Tofacitinib
1
Adverse events — posted to ClinicalTrials.gov
Time frame: Patients came back for follow-up every month during a total of 24 weeks of treatments and at weeks 28,36 and 48..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The objective of this study is to assess the safety and efficacy of Tofacitinib in treating patients with extensive and recalcitrant Alopecia Areata (AA), along with to evaluate the economic impact of the patients that may be from changing in their quality of life. There are patients with severe AA who may have little or no improvement from the treatment by diphenylcyclopropenone (DPCP) or topical steroid with minoxidil but instead having positive response from the treatment with Janus kinase(JAK) inhibitor such as Tofacitinib or Ruxolitinib. For the best of my knowledge, there was no previous study in using Tofacitinib to treat severe AA before in Thailand.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07530367 — A Phase III Randomized Controlled Trial Evaluating the Efficacy and Safety of Tofacitinib Combined With Imatinib in Pati
· Phase 3
· not yet recruiting
NCT07406204 — Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
· Phase 4
· not yet recruiting
NCT07343635 — The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined
· NA
· recruiting
NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
· Phase 4
· not yet recruiting
NCT07297069 — Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial
· Phase 2
· not yet recruiting
Other recruiting trials for Alopecia Areata
Currently open trials in the same condition.
NCT07242638 — Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
· Phase 2
· recruiting
NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata
· Phase 2
· recruiting
NCT07250997 — PALLAS Laser for Skin Diseases
· NA
· recruiting
NCT07205159 — A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
· Phase 1
· recruiting
NCT06747611 — Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata
· Phase 2
· recruiting
Other Institute of Dermatology, Thailand trials
Trials by the same sponsor.
NCT07536100 — VENEZE Peptide Factor Hair Serum Compared With Topical 2% Minoxidil for Androgenetic Alopecia
· NA
· not yet recruiting
NCT07503197 — A Pilot Study on the Efficacy of 2% Cholesterol Cream in Preventing Transepidermal Water Loss and Clinical Symptoms in M
· NA
· enrolling by invitation
NCT07433907 — Efficacy of an Antioxidant Moisturizing Serum for Mild to Moderate Seborrheic Dermatitis
· NA
· recruiting
NCT06202560 — Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
· NA
· completed
NCT05724589 — The Effectiveness of Epidermal Growth Factor Serum in Improve Facial Skin Hydration, Elasticity, Pigmentation, and Wrink
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Dermatology, Thailand
Last refreshed: 31 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03800979.